IP Library Granted Patent US 11,464,423
Granted Patent B2
US 11,464,423 · App. 14/602,895 · Granted Oct 11, 2022

In-body power source having high surface area electrode

Inventors: Hooman Hafezi (Redwood City, CA); Timothy Robertson (Belmont, CA); Eric Snyder (South San Francisco, CA); Brad Cozad (Newark, CA)
Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
A61B5/073A61B5/0028A61J3/07A61M31/00C23C14/325C25D9/04C25D13/02H01M4/02H01M4/0416H01M4/0426H01M4/668H01M6/34H01M8/08H01M10/0436A61B2560/0214A61B2560/04A61B2562/12A61N1/378G08C2200/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,464,423
App. No.
14/602,895
Granted
Oct 11, 2022
Kind
B2
Abstract

Power sources that enable in-body devices, such as implantable and ingestible devices, are provided. Aspects of the in-body power sources of the invention include a solid support, a first high surface area electrode and a second electrode. Embodiments of the in-power sources are configured to emit a detectable signal upon contact with a target physiological site. Also provided are methods of making and using the power sources of the invention.

Claims (38)

1. An in-body medical device comprising:

an integrated circuit substrate comprising a surface and a circuitry element;

a first electrode coupled to the circuitry element and comprising:

a first active electrode material;

a first surface; and

a second surface;

a second electrode connected to the surface of the integrated circuit substrate and coupled to the circuitry element, wherein the second electrode is electrically isolated from the first electrode and comprises a second active electrode material that is different from the first active electrode material; and

an electrically conductive porous under-layer interposed between the first surface of the first electrode and the surface of the integrated circuit substrate, the electrically conductive porous under-layer comprising an inert metal or an oxidizable metal; wherein the electrically conductive porous under-layer is configured to provide a surface area enhancement to the first electrode, wherein the electrically conductive porous under-layer is configured to improve adhesion, and wherein the electrically conductive porous under-layer is a layer that is contiguous to and mechanically supports the first electrode; and

wherein the in-body medical device is suitable for human ingestion or implantation.

2. The in-body medical device according to claim 1 , wherein the device is dimensioned to be ingestible.

3. The in-body medical device according to claim 1 , wherein the electrically conductive porous under-layer comprises an element selected from the group consisting of: Au, Cu, Pt, Ir, Pd, Rh and Ru and alloys thereof.

4. The in-body medical device according to claim 1 , wherein the electrically conductive porous under-layer comprises an element selected from the group consisting of: Ti and W and alloys thereof.

5. The in-body medical device according to claim 1 , wherein the electrically conductive porous under-layer has a thickness ranging from 0.1 to 100 μm.

6. The in-body medical device according to claim 1 , wherein the first electrode is formed on the same surface of the integrated circuit substrate as the second electrode.

7. The in-body medical device according to claim 1 , wherein:

the surface of the integrated circuit substrate comprises a first substrate surface to which the first electrode is connected via the electrically conductive porous under-layer and a second substrate surface to which the second electrode is connected; and

the first substrate surface is arranged opposite to the second substrate surface.

8. The in-body medical device according to claim 1 , wherein the device comprises a pharmaceutically acceptable carrier composition.

9. The in-body medical device according to claim 8 , wherein the pharmaceutically acceptable carrier composition is in the form of a tablet.

10. The in-body medical device according to claim 8 , wherein the pharmaceutically acceptable carrier composition is in the form of a capsule.

11. The in-body medical device according to claim 8 , wherein the pharmaceutically acceptable carrier composition comprises an active agent.

12. The device of claim 1 , wherein the second surface is uncovered by the electrically conductive porous under-layer.

13. A system comprising:

a receiver; and

an in-body medical device suitable for human ingestion or implantation, wherein the in- body medical device is configured to communicate with the receiver, the in-body medical device comprising:

an integrated circuit substrate comprising a surface and a circuitry element;

a first electrode coupled to the circuitry element and comprising:

a first active electrode material;

a first surface; and

a second surface;

a second electrode connected to the surface of the integrated circuit substrate and coupled to the circuitry element, wherein the second electrode is electrically isolated from the first electrode and comprises a second active electrode material that is different from the first active electrode material; and

an electrically conductive porous under-layer interposed between the first surface of the first electrode and the surface of the integrated circuit substrate, the electrically conductive porous under-layer comprising an inert metal or an oxidizable metal; wherein the electrically conductive porous under-layer is configured to provide a surface area enhancement to the first electrode, wherein the electrically conductive porous under-layer is configured to improve adhesion, and wherein the electrically conductive porous under-layer is a layer that is contiguous to and mechanically supports the first electrode.

14. The system according to claim 13 , wherein said receiver is an in vivo receiver.

15. The system according claim 13 , wherein said receiver is an ex vivo receiver.

16. The system according to claim 13 , wherein the electrically conductive porous under-layer is provided by electrodeposition.

17. The system according to claim 13 , wherein the electrically conductive porous under-layer is provided by cathodic arc deposition.

18. The system according to claim 13 , wherein the electrically conductive porous under-layer is provided by electrophoretic deposition.

19. The system of claim 13 , wherein the second surface is uncovered by the electrically conductive porous under-layer.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2021
From: OTSUKA AMERICA PHARMACEUTICAL, INC.
To: OTSUKA PHARMACEUTICAL CO., LTD.
Reel/Frame 056239/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2021
From: PROTEUS DIGITAL HEALTH, INC.
To: OTSUKA AMERICA PHARMACEUTICAL, INC.
Reel/Frame 055704/0609 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2015
From: HAFEZI, HOOMAN; ROBERTSON, TIMOTHY; SNYDER, ERIC; COZAD, BRAD
To: PROTEUS BIOMEDICAL, INC.
Reel/Frame 035548/0797 →
CHANGE OF NAME Recorded May 1, 2015
From: PROTEUS BIOMEDICAL, INC.
To: PROTEUS DIGITAL HEALTH, INC.
Reel/Frame 035561/0298 →
Continuity (3)
Continuation 12527190
Provisional Application 60889870 · Feb 14, 2007
Related Publication 20150230728A1 · Aug 20, 2015